Yu Zhiyuan, Tu Huaiyu, Qiu Shuzhong, Dong Xiaoyu, Zhang Yonghui, Ma Chao, Li Peiyu
School of Medicine, Nankai University, Nankai District, Tianjin; Medical School of Chinese PLA; Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Haidian District, Beijing, China.
Medical School of Chinese PLA; Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Haidian District, Beijing, China.
J Minim Access Surg. 2023 Jul-Sep;19(3):335-347. doi: 10.4103/jmas.jmas_170_22.
This study aimed to evaluate the efficacy of multidisciplinary treatment for patients with locally advanced gastric cancer (LAGC) who underwent radical gastrectomy.
Randomised controlled trials (RCTs) comparing the effectiveness of surgery alone, adjuvant chemotherapy (CT), adjuvant radiotherapy (RT), adjuvant chemoradiotherapy (CRT), neoadjuvant CT, neoadjuvant RT, neoadjuvant CRT, perioperative CT and hyperthermic intraperitoneal chemotherapy (HIPEC) for LAGC were searched. Overall survival (OS), disease-free survival (DFS), recurrence and metastasis, long-term mortality, adverse events (grade ≥3), operative complications and R0 resection rate were used as outcome indicators for meta-analysis.
Forty-five RCTs with 10077 participants were finally analysed. Adjuvant CT had higher OS (hazard ratio [HR] = 0.74, 95% credible interval [CI] = 0.66-0.82) and DFS (HR = 0.67, 95% CI = 0.60-0.74) than surgery-alone group. Perioperative CT (odds ratio [OR] = 2.56, 95% CI = 1.19-5.50) and adjuvant CT (OR = 0.48, 95% CI = 0.27-0.86) both had more recurrence and metastasis than HIPEC + adjuvant CT, while adjuvant CRT tended to have less recurrence and metastasis than adjuvant CT (OR = 1.76, 95% CI = 1.29-2.42) and even adjuvant RT (OR = 1.83, 95% CI = 0.98-3.40). Moreover, the incidence of mortality in HIPEC + adjuvant CT was lower than that in adjuvant RT (OR = 0.28, 95% CI = 0.11-0.72), adjuvant CT (OR = 0.45, 95% CI = 0.23-0.86) and perioperative CT (OR = 2.39, 95% CI = 1.05-5.41). Analysis of adverse events (grade ≥3) showed no statistically significant difference between any two adjuvant therapy groups.
A combination of HIPEC with adjuvant CT seems to be the most effective adjuvant therapy, which contributes to reducing tumour recurrence, metastasis and mortality - without increasing surgical complications and adverse events related to toxicity. Compared with CT or RT alone, CRT can reduce recurrence, metastasis and mortality but increase adverse events. Moreover, neoadjuvant therapy can effectively improve the radical resection rate, but neoadjuvant CT tends to increase surgical complications.
本研究旨在评估接受根治性胃切除术的局部晚期胃癌(LAGC)患者多学科治疗的疗效。
检索比较单纯手术、辅助化疗(CT)、辅助放疗(RT)、辅助放化疗(CRT)、新辅助CT、新辅助RT、新辅助CRT、围手术期CT及热灌注腹腔化疗(HIPEC)治疗LAGC有效性的随机对照试验(RCT)。总生存期(OS)、无病生存期(DFS)、复发与转移、长期死亡率、不良事件(≥3级)、手术并发症及R0切除率用作荟萃分析的结局指标。
最终分析了45项RCT,共10077名参与者。辅助CT组的OS(风险比[HR]=0.74,95%可信区间[CI]=0.66-0.82)和DFS(HR=0.67,95%CI=0.60-0.74)均高于单纯手术组。围手术期CT(优势比[OR]=2.56,95%CI=1.19-5.50)和辅助CT(OR=0.48,95%CI=0.27-0.86)的复发与转移均多于HIPEC+辅助CT组,而辅助CRT组的复发与转移倾向少于辅助CT组(OR=1.76,95%CI=1.29-2.42),甚至少于辅助RT组(OR=1.83,95%CI=0.98-3.40)。此外,HIPEC+辅助CT组的死亡率低于辅助RT组(OR=0.28,95%CI=0.11-0.72)、辅助CT组(OR=0.45,95%CI=0.23-0.86)和围手术期CT组(OR=2.39,95%CI=1.05-5.41)。不良事件(≥3级)分析显示,任何两个辅助治疗组之间均无统计学显著差异。
HIPEC与辅助CT联合似乎是最有效的辅助治疗方法,有助于降低肿瘤复发、转移和死亡率,且不增加手术并发症及与毒性相关的不良事件。与单纯CT或RT相比,CRT可降低复发、转移和死亡率,但会增加不良事件。此外,新辅助治疗可有效提高根治性切除率,但新辅助CT倾向于增加手术并发症。